Arnol 2011.

Methods	Study design: parallel RCT Duration of study: not reported Duration of follow‐up: 24 weeks
Participants	Country: Slovenia Setting: single centre Inclusion criteria: kidney transplant recipients at least 3 months' post transplant with UPCR ≥ 20 mg/mmol despite optimisation of RAAS blockade during run‐in phase Number: treatment group (83); control group (85) Mean age ± SD (years): not reported Sex (M/F): not reported Exclusion criteria: not reported
Interventions	Treatment group Paricalcitol: 2 µg/d Control group Placebo Co‐interventions Not reported
Outcomes	UPCR UACR IL6 and TGF‐beta plasma concentrations
Notes	Abstract‐only publication, no full‐text publication identified Funding source: not reported Trial registration: not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Double‐blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Double‐blinded
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	High risk	Patient‐level outcomes including adverse events were not systematically reported
Other bias	Unclear risk	Insufficient information to permit judgement